BUTAZOLIDIN
LOE ApproachingNDAORALCAPSULE
Approved
Jun 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BUTAZOLIDIN is an oral small-molecule capsule approved by Novartis in 1997. Specific indication and mechanism of action data are not available in current records. This product represents a legacy small-molecule therapeutic in a mature market.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30%), signaling a contracting brand team focused on managed decline and legacy market maintenance.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings suggest minimal active hiring for BUTAZOLIDIN teams. This is a legacy asset nearing exclusivity loss, offering limited career advancement and growth opportunities. Roles available are primarily focused on managing market decline and transitioning to generic competition.
Brand ManagerField Sales Representative
Worked on BUTAZOLIDIN at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.